Virginiamycin S3
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-02967 |
| CAS | 33477-39-3 |
| Molecular Weight | 839.89 |
| Molecular Formula | C43H49N7O11 |
Online Inquiry
Description
It is a depsipeptide antibiotic produced by the strain of Str. virginiae and Str. virginiae var. sp. It has anti-gram-positive bacteria and mycobacterium effects, and the antibacterial activity of component M of Virginiamycin against cocci is stronger than component S, while the activity is stronger than component M.
Specification
| Synonyms | Staphylomycin S3; Virginiamycin S1, 5-(5-hydroxy-4-oxo-L-2-piperidinecarboxylic acid)-; N-[(3-Hydroxy-2-pyridinyl)carbonyl]cyclo[L-Thr*-D-Abu-L-Pro-N-methyl-L-Phe-4-oxo-5-hydroxy-L-pipecoloyl-L-phenyl-Gly-] |
| IUPAC Name | N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-25-hydroxy-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentazatricyclo[20.4.0.06,10]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide |
| Canonical SMILES | CCC1C(=O)N2CCCC2C(=O)N(C(C(=O)N3CC(C(=O)CC3C(=O)NC(C(=O)OC(C(C(=O)N1)NC(=O)C4=C(C=CC=N4)O)C)C5=CC=CC=C5)O)CC6=CC=CC=C6)C |
| InChI | InChI=1S/C43H49N7O11/c1-4-27-40(57)49-20-12-17-28(49)41(58)48(3)30(21-25-13-7-5-8-14-25)42(59)50-23-33(53)32(52)22-29(50)37(54)47-35(26-15-9-6-10-16-26)43(60)61-24(2)34(38(55)45-27)46-39(56)36-31(51)18-11-19-44-36/h5-11,13-16,18-19,24,27-30,33-35,51,53H,4,12,17,20-23H2,1-3H3,(H,45,55)(H,46,56)(H,47,54)/t24-,27-,28+,29+,30+,33?,34+,35+/m1/s1 |
| InChI Key | AVCLYXFQZNDKMW-ADDARJJRSA-N |
Properties
| Appearance | White Acicular Crystal |
| Antibiotic Activity Spectrum | Gram-positive bacteria; Mycobacteria |
| Boiling Point | 1215.6±65.0°C (Predicted) |
| Density | 1.43±0.1 g/cm3 (Predicted) |
| Solubility | Soluble in Methanol, Ethanol |
Reference Reading
1. Antimicrobial susceptibility of Gram-positive bacteria: what's current, what's anticipated?
A P Johnson, D M Livermore, G S Tillotson J Hosp Infect. 2001 Dec;49 Suppl A:S3-11. doi: 10.1016/s0195-6701(01)90029-5.
Changing patterns of pathogens and antibiotic susceptibility present clinicians with difficult choices for antimicrobial prescribing. In particular, multiresistant staphylococci, enterococci and pneumococci present problems in many settings. The number of predictably active antimicrobials is decreasing in many centres, with significant consequences for both patients and society as a whole. New antimicrobial options have been few in recent years and several promising quinolones have been compromised by formulation and/or toxicity issues. Nevertheless, the recent introduction of linezolid and quinupristin/dalfopristin provides clinicians with valuable new options against Gram-positive cocci. These options should further increase with the likely introduction of daptomycin, oritavancin and tigilcycline. A range of surveillance programmes helps monitor the ever-changing patterns of resistance and thus guides clinicians in their empirical prescribing. Empirical use of powerful newer agents may be justifiable in seriously ill patients in those settings, units and countries where there is a substantial background rate of resistance.
Recommended Products
| BBF-03921 | Staurosporine | Inquiry |
| BBF-03963 | Pristinamycin | Inquiry |
| BBF-03816 | Milbemycin oxime | Inquiry |
| BBF-03884 | Formononetin | Inquiry |
| BBF-01851 | Fumagillin | Inquiry |
| BBF-04736 | 3-Indolepropionic acid | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
